A
6.45
0.04 (0.62%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Aura Biosciences, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-0.1
| 分析师共识 | 2.0 |
| 内部交易活动 | 1.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.10 |
|
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.98% |
| 机构持股比例 | 76.19% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Matrix Capital Management Company, Lp | 31 Mar 2026 | 6,922,870 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BITETTI TERESA MARIE | 6.21 | - | 15,000 | 93,150 |
| JOHNSON DAVID MICHAEL | 6.21 | - | 15,000 | 93,150 |
| MATTESSICH ANTONY C. | 6.21 | - | 15,000 | 93,150 |
| SRIVASTAVA SAPNA | 6.21 | - | 15,000 | 93,150 |
| 累积净数量 | 60,000 | |||
| 累积净值 ($) | 372,600 | |||
| 累积平均购买 ($) | 6.21 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MATTESSICH ANTONY C. | 董事 | 11 Jun 2026 | 获得 (+) | 15,000 | 6.21 | 93,150 |
| JOHNSON DAVID MICHAEL | 董事 | 11 Jun 2026 | 获得 (+) | 15,000 | 6.21 | 93,150 |
| SRIVASTAVA SAPNA | 董事 | 11 Jun 2026 | 获得 (+) | 15,000 | 6.21 | 93,150 |
| BITETTI TERESA MARIE | 董事 | 11 Jun 2026 | 获得 (+) | 15,000 | 6.21 | 93,150 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合